On Thursday, BofA Securities adjusted its stance on Alignment Healthcare Inc (NASDAQ:ALHC), upgrading the stock from Neutral to Buy and increasing the price target to $11.00 from $7.50. The firm cited improved visibility into the company's margin progression as the primary reason for the change.
Alignment Healthcare is reportedly shifting its focus towards improving margins rather than concentrating solely on growth, a strategic pivot since its initial public offering. According to BofA Securities, this new direction comes at a time when most of Alignment Healthcare's competitors are grappling with significant challenges, allowing the company to reduce benefits and boost profitability without losing market share.
The analyst noted that forward profit estimates for Alignment Healthcare have been raised above the consensus, with expectations of $0.50 GAAP earnings per share (EPS) by 2027, significantly higher than the street's projection of $0.01.
This anticipated increase in profits has been valued using a 30 times price-to-earnings (P/E) multiple on the 2027 estimated GAAP EPS, up from a 24 times multiple on the 2026 estimate. The new valuation also incorporates a 30% discount rate, equating to 15% per year.
The raised price target reflects a P/E multiple that is roughly twice as high as that of other managed care organizations (MCOs), justified by Alignment Healthcare's higher growth potential. Key upcoming catalysts for the company include an easing of utilization fears by the second or third quarter and the potential for the 2025 guidance to reveal substantial margin expansion beyond current expectations.
The report draws a parallel with another small to mid-cap (SMID) insurer, citing a historical instance where a significant shift to profitability led to the doubling of the stock value.
InvestingPro Insights
As BofA Securities shines a spotlight on Alignment Healthcare's (NASDAQ:ALHC) strategic shift toward margin improvement, real-time data from InvestingPro further contextualizes the company's financial landscape.
With a market capitalization of $1.33 billion, Alignment Healthcare is trading at a high Price / Book multiple of 10.19, which underscores the firm's growth-oriented valuation strategy as noted by BofA Securities. Moreover, the company's revenue growth stands out, with an impressive 31.76% increase over the last twelve months as of Q1 2024, alongside a quarterly growth of 43.14% in Q1 2024, indicating robust sales performance.
InvestingPro Tips highlight that Alignment Healthcare holds more cash than debt on its balance sheet, suggesting a solid liquidity position that could support its strategic initiatives. However, analysts have tempered their earnings outlook, with two revisions pointing downwards for the upcoming period. This aligns with BofA's focus on the company's long-term profitability rather than short-term earnings.
With a strong return over the last month of 35.53% and over the last three months of 16.33%, investors may find the recent performance encouraging, though analysts do not anticipate the company to be profitable this year.
For investors seeking a more comprehensive analysis, InvestingPro offers additional insights beyond these highlights. Those interested in delving deeper can take advantage of the exclusive coupon code PRONEWS24 for an additional 10% off a yearly or biyearly Pro and Pro+ subscription, which includes a wider array of InvestingPro Tips for a thorough investment strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.